Patents by Inventor Thomas Matthes

Thomas Matthes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BARBITURIC ACID DERIVATIVES, THEIR PREPARATION AND USE THEREOF AS LEUKOCYTE TRANSMIGRATION INHIBITORS AND FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
    Publication number: 20230150949
    Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 18, 2023
    Inventors: Arie Lev GRUZMAN, Paul BRADFIELD, Tamar GETTER, Beat IMHOF, Thomas MATTHES, Hanoch SENDEROWITZ
  • Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
    Patent number: 11492333
    Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignees: BAR-ILAN UNIVERSITY, UNIVERSITY OF GENEVA, GENEVA UNIVERSITY HOSPITALS
    Inventors: Arie Lev Gruzman, Paul Bradfield, Tamar Getter, Beat Imhof, Thomas Matthes, Hanoch Senderowitz
  • JAM-C antibodies and methods for treatment of cancer
    Patent number: 10759857
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 1, 2020
    Assignee: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate
  • NOVEL BARBITURIC ACID DERIVATIVES, THEIR PREPARATION AND USE THEREOF AS LEUKOCYTE TRANSMIGRATION INHIBITORS AND FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
    Publication number: 20200181094
    Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
    Type: Application
    Filed: August 30, 2018
    Publication date: June 11, 2020
    Inventors: Arie Lev GRUZMAN, Paul BRADFIELD, Tamar GETTER, Beat IMHOF, Thomas MATTHES, Hanoch SENDEROWITZ
  • JAM-C antibodies and methods for treatment of cancer
    Patent number: 10385129
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 20, 2019
    Assignee: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate
  • JAM-C ANTIBODIES AND METHODS FOR TREATMENT OF CANCER
    Publication number: 20180171013
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Application
    Filed: February 1, 2018
    Publication date: June 21, 2018
    Applicant: Research Development Foundation
    Inventors: Beat IMHOF, Christiane ODY, Thomas MATTHES, Carmen DONATE
  • JAM-C antibodies and methods for treatment of cancer
    Patent number: 9803014
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 31, 2017
    Assignee: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate
  • JAM-C ANTIBODIES AND METHODS FOR TREATMENT OF CANCER
    Publication number: 20170291944
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Applicant: Research Development Foundation
    Inventors: Beat IMHOF, Christiane ODY, Thomas MATTHES, Carmen DONATE
  • JAM-C ANTIBODIES AND METHODS FOR TREATMENT OF CANCER
    Publication number: 20150246971
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Application
    Filed: October 24, 2013
    Publication date: September 3, 2015
    Applicant: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate